+

WO2003017920A3 - Protective factors against inflammation, burns and noxious stimuli - Google Patents

Protective factors against inflammation, burns and noxious stimuli Download PDF

Info

Publication number
WO2003017920A3
WO2003017920A3 PCT/IL2002/000713 IL0200713W WO03017920A3 WO 2003017920 A3 WO2003017920 A3 WO 2003017920A3 IL 0200713 W IL0200713 W IL 0200713W WO 03017920 A3 WO03017920 A3 WO 03017920A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
noxious stimuli
burns
against inflammation
protective factors
Prior art date
Application number
PCT/IL2002/000713
Other languages
French (fr)
Other versions
WO2003017920A2 (en
Inventor
Uri Wormser
Original Assignee
Yissum Res Dev Co
Uri Wormser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Uri Wormser filed Critical Yissum Res Dev Co
Priority to AU2002329017A priority Critical patent/AU2002329017A1/en
Priority to EP02765303A priority patent/EP1572069A4/en
Publication of WO2003017920A2 publication Critical patent/WO2003017920A2/en
Priority to US10/790,888 priority patent/US7238656B2/en
Publication of WO2003017920A3 publication Critical patent/WO2003017920A3/en
Priority to US11/750,408 priority patent/US7605132B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Peptide factors isolated from skin following exposure to chemical or thermal injury and treatment with iodine preparations are capable of reducing or ameliorating the extent of injury when administered to other animals. Specific peptides, including fragments of histone H2A and fibrinopeptide A, and preferred derivatives of these peptides are disclosed. Pharmaceutical compositions and methods of using these peptides are also disclosed. The extracts, peptides and pharmaceutical compositions according to the invention are useful for the prevention and treatment of inflammatory conditions and exposure to noxious stimuli.
PCT/IL2002/000713 2001-08-29 2002-08-29 Protective factors against inflammation, burns and noxious stimuli WO2003017920A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002329017A AU2002329017A1 (en) 2001-08-29 2002-08-29 Protective factors against inflammation, burns and noxious stimuli
EP02765303A EP1572069A4 (en) 2001-08-29 2002-08-29 Protective factors against inflammation, burns and noxious stimuli
US10/790,888 US7238656B2 (en) 2001-08-29 2004-03-01 Protective factors against inflammation, burns and noxious stimuli
US11/750,408 US7605132B2 (en) 2001-08-29 2007-05-18 Protective factors against inflammation, burns and noxious stimuli

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL145181 2001-08-29
IL145181A IL145181A0 (en) 2001-08-29 2001-08-29 Protective factors against burns and noxious stimuli

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/527,162 Continuation-In-Part US7528227B2 (en) 2001-08-29 2006-09-25 Histone H2A peptide derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/790,888 Continuation US7238656B2 (en) 2001-08-29 2004-03-01 Protective factors against inflammation, burns and noxious stimuli

Publications (2)

Publication Number Publication Date
WO2003017920A2 WO2003017920A2 (en) 2003-03-06
WO2003017920A3 true WO2003017920A3 (en) 2006-08-10

Family

ID=11075745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000713 WO2003017920A2 (en) 2001-08-29 2002-08-29 Protective factors against inflammation, burns and noxious stimuli

Country Status (4)

Country Link
EP (1) EP1572069A4 (en)
AU (1) AU2002329017A1 (en)
IL (1) IL145181A0 (en)
WO (1) WO2003017920A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528227B2 (en) 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof
WO2005090387A2 (en) * 2004-03-23 2005-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone h2a peptide derivatives and analogs and methods of use thereof
US7605132B2 (en) 2001-08-29 2009-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
WO2006101187A1 (en) * 2005-03-22 2006-09-28 Rohto Pharmaceutical Co., Ltd. Peptides that increase collagen or hyaluronic acid production
EP2558110B1 (en) * 2010-04-11 2015-06-03 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Extract and peptides derived from oryza sativa japonica group and uses thereof
CN106397575A (en) * 2016-10-20 2017-02-15 上海懿贝瑞生物医药科技有限公司 Preparation method and application of polypeptide with ectoenzyme histone toxicity inhibition function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750920A1 (en) * 1977-11-15 1979-05-17 Max Planck Gesellschaft Therapeutic agent for internal inflammatory diseases - contains plasma protein and fibrinogen used to treat e.g. septicaemia or erysipelas
WO2001038522A1 (en) * 1999-11-23 2001-05-31 Bioroad Gene Development Ltd. Shanghai A novel polypeptide, a human histone h2a.21 and the polynucleotide encoding the polypeptide
US20030007964A1 (en) * 1998-01-24 2003-01-09 Samyang Genex Corporation Method for treating rheumatoid arthritis with composition containing histone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599790A (en) * 1992-06-11 1997-02-04 The Scripps Research Institute Fibrinogen γ chain polypeptide and compositions thereof
WO2000064466A1 (en) * 1999-04-28 2000-11-02 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750920A1 (en) * 1977-11-15 1979-05-17 Max Planck Gesellschaft Therapeutic agent for internal inflammatory diseases - contains plasma protein and fibrinogen used to treat e.g. septicaemia or erysipelas
US20030007964A1 (en) * 1998-01-24 2003-01-09 Samyang Genex Corporation Method for treating rheumatoid arthritis with composition containing histone
WO2001038522A1 (en) * 1999-11-23 2001-05-31 Bioroad Gene Development Ltd. Shanghai A novel polypeptide, a human histone h2a.21 and the polynucleotide encoding the polypeptide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] "Pharmaceutical composition containing fibrinopeptides A or B", XP008100372, accession no. STN Database accession no. (1979:563038) *
DATABASE MEDLINE [online] ELGJO K. ET AL.: "Proliferation-dependent effect of skin extracts (chalone) on mouse epidermal cell flux at the G1-S, S-G2 and G2-M transitions", XP008099665, accession no. STN Database accession no. (83199201) *
DATABASE WPIDS [online] MAO,Y ET AL: "New human histone H2A.21 for diagnosing and treating malignant tumor, hemopathy, human immunodeficiency virus (HIV) infection, immunological diseases and inflammation", XP008099658, accession no. STN Database accession no. (2001-355930) *
VIRCHOWS ARCHIV. B, vol. 42, no. 2, 1983, pages 143 - 151 *

Also Published As

Publication number Publication date
AU2002329017A8 (en) 2006-11-09
EP1572069A4 (en) 2009-06-24
IL145181A0 (en) 2009-02-11
WO2003017920A2 (en) 2003-03-06
AU2002329017A1 (en) 2003-03-10
EP1572069A2 (en) 2005-09-14

Similar Documents

Publication Publication Date Title
NO20042298L (en) Pharmaceutical preparations and their uses
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
BR9710372A (en) Compound pharmaceutical composition and processes for the treatment of an inflammatory disease and diseases mediated by cliclooxygenase
WO2002046129A3 (en) Inhibitors of histone deacetylase
HUP0003280A3 (en) Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders
EA200100872A1 (en) COMPOSITION VALDEKOKSIBA
HUP9901144A2 (en) Pharmaceutical compositions containing new associations of clopidogrel and an antithrombotic agent
WO1998006742A3 (en) Peptides for treatment of inflammation and shock
WO2004043352A8 (en) Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
PL323364A1 (en) Bicyclic aromatic compounds
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
BRPI0415755A (en) bradykinin b1 receptor antagonists
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DK1032556T3 (en) Pharmaceutically active compounds and methods of use
BR9810755A (en) CD 154 blocking therapy for therapeutic protein inhibitory syndrome
PL323363A1 (en) Biaromatic propynyl or dienyl compounds
WO2003017920A3 (en) Protective factors against inflammation, burns and noxious stimuli
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
TR200100637T2 (en) New natural product derivatives
WO2000078795A3 (en) Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
EP0821969A3 (en) Medicinal Composition comprising TCF-II

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002765303

Country of ref document: EP

Ref document number: 10790888

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002765303

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载